Exact Therapeutics AS

Exact Therapeutics AS EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Exact Therapeutics AS (EXTX.OL) as of Oct 22, 2026 is -1.45. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.33 — a change of -37.73% (higher).

EV/EBIT

-1.45

YoY

-37.73%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Exact Therapeutics AS is 2025 -1.45 . EV/EBIT (Enterprise Value to EBIT) of Exact Therapeutics AS was 2024 -2.33 . It decreases by -37.73% higher compared to the previous year.

The Exact Therapeutics AS EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-16.18 NOK
Jan 1, 2019
-7.72 NOK
Jan 1, 2020
-3.56 NOK
Jan 1, 2021
-2.09 NOK
Jan 1, 2022
-3.03 NOK
Jan 1, 2023
-2.55 NOK
Jan 1, 2024
-2.33 NOK
Jan 1, 2025
-1.45 NOK
The Exact Therapeutics AS EV/EBIT history
YEAREV/EBITYoY
-1.45-37.73%
-2.33-8.47%
-2.55-15.72%
-3.03+44.97%
-2.09-41.30%
-3.56-53.94%
-7.72-52.30%
-16.18-35.03%
-24.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Exact Therapeutics AS Stock analysis

What does Exact Therapeutics AS do? Exact Therapeutics AS develops ACT sonoporation, a platform for ultrasound-mediated targeted drug enhancement to amplify therapeutic agents' clinical utility across cancer, infectious diseases, and neurological conditions. The company monetizes through research and development services for pharmaceutical partners seeking to enhance existing drug therapies with ultrasound targeting. Its primary customers are biopharmaceutical firms aiming to improve chemotherapy, immunotherapy, and other treatments. The firm's purpose centers on extending patient lives through targeted therapeutic enhancement using ultrasound and ACT formulation. Exact Therapeutics AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exact Therapeutics AS stock

EV/EBIT (Enterprise Value to EBIT) of Exact Therapeutics AS is -1.45 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Exact Therapeutics AS changed from -2.33 to -1.45, representing a -37.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Exact Therapeutics AS since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Exact Therapeutics AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Exact Therapeutics AS

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Exact Therapeutics AS